Enter inventor name

Average Co-Inventor Count = 5.8

ph-index = 3

Forward Citations = 27(Granted Patents)

Location History:

Weesp, NL (2006 - 2016)
Hoofddorp, NL (2014 - 2022)

Company Filing History:

Solvay Pharmaceuticals, B.v.

patents

4. 2 out of 6

Abbvie Bahamas Limited

Abbvie Deutschland Gmbh and Co Kg

patents

where one patent can have more than one assignee

Years Active: 2006-2022

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11427598 - Spiro-cyclic amine derivatives as S1P modulators (2022-08-30),

2. RE48301 - Fused heterocyclic derivatives as S1P modulators (2020-11-09),

3. 10807991 - Spiro-cyclic amine derivatives as S1P modulators (2020-10-20),

4. 10179791 - Spiro-cyclic amine derivatives as S1P modulators (2019-01-15),

5. 9951084 - Spiro-cyclic amine derivatives as S1P modulators (2018-04-24),

6. 9670220 - Fused heterocyclic derivatives as S1P modulators (2017-06-06),

7. 9273017 - (Thio)morpholine derivatives as S1P modulators (2016-03-01),

8. 9096612 - Fused heterocyclic derivatives as S1P modulators (2015-08-04),

9. 9045441 - (Thio)morpholine derivatives as S1P modulators (2015-06-02),

10. 8796262 - Fused heterocyclic derivatives as S1P modulators (2014-08-05),

11. 8735388 - Heterocyclic compounds with affinity to muscarinic receptors (2014-05-27),

12. 8586606 - Heterocyclic compounds with affinity to muscarinic receptors (2013-11-19),

13. 8252930 - Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition (2012-08-28),

14. 8084473 - Heterocyclic compounds with affinity to muscarinic receptors (2011-12-27),

15. 7964728 - Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition (2011-06-21),

Title: The Innovative Contributions of Hein K A C Coolen

Introduction

Hein K A C Coolen is a notable inventor based in Weesp, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that modulate S1P receptors. With a total of 17 patents to his name, Coolen's work has the potential to impact the treatment of various diseases.

Latest Patents

Among his latest patents, Coolen has developed spiro-cyclic amine derivatives as S1P modulators. This invention relates to spiro-cyclic amine derivatives of a specific formula, which may be used in the treatment, alleviation, or prevention of diseases involving S1P receptors. Another significant patent involves fused heterocyclic derivatives as S1P modulators. This invention focuses on new fused heterocyclic derivatives that have affinity to S1P receptors and can be used in pharmaceutical compositions for treating conditions related to S1P signaling.

Career Highlights

Coolen has worked with prominent companies in the pharmaceutical industry, including AbbVie B.V. and AbbVie Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Hein K A C Coolen has collaborated with notable colleagues such as Wouter I Iwema Bakker and Axel Stoit. These collaborations have likely enhanced his research and development efforts in the pharmaceutical field.

Conclusion

Hein K A C Coolen's innovative work in the development of S1P modulators showcases his significant contributions to pharmaceutical science. His patents reflect a commitment to advancing medical treatments and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com